Related Experiment Video

Updated: Feb 26, 2026

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
08:02

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids

Published on: April 25, 2016

10.1K

New anti-inflammatory metabolites produced by Streptomyces violaceoruber isolated from Equus burchelli feces

Jian Ma1, Hui Lei1, Xiu Chen2

  • 1Institute of Microbial Pharmaceuticals, College of Life and Health Sciences, Northeastern University, Shenyang, PR China.

The Journal of Antibiotics
|July 13, 2017
PubMed

More Related Videos

Author Spotlight: Isolation and Characterization of Equine Submucosal Enteric Glia — Implications for Preventing Postoperative Complications in Colic Surgery08:07

Author Spotlight: Isolation and Characterization of Equine Submucosal Enteric Glia — Implications for Preventing Postoperative Complications in Colic Surgery

Published on: October 4, 2024

871
Development of an in vitro model system for studying the interaction of Equus caballus IgE with its high-affinity receptor FcεRI07:31

Development of an in vitro model system for studying the interaction of Equus caballus IgE with its high-affinity receptor FcεRI

Published on: November 1, 2014

13.0K

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.3K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
852
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
577